Neuvivo Appoints Mark Henderson, PhD, to Lead Manufacturing for ALS Treatment
Thursday, 22 August 2024, 06:09
Neuvivo Strengthens Technical Operations
Neuvivo, a biopharmaceutical company focused on groundbreaking therapies for Amyotrophic Lateral Sclerosis (ALS), announced the significant appointment of Mark Henderson, PhD, as Vice President of Manufacturing. This role is pivotal in enhancing technical operations and ensuring the success of their investigational ALS treatment.
Impact of the Appointment
- Dr. Henderson brings a wealth of experience in manufacturing and operations.
- His role will accelerate the development and production processes for Neuvivo’s therapies.
- The strategic appointment signals Neuvivo's commitment to advancing treatments for neurodegenerative diseases.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.